Statistics for CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
Total visits
| views | |
|---|---|
| CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study | 2 |
Total visits per month
| views | |
|---|---|
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
File Visits
| views | |
|---|---|
| java.util.UUID:f4d72f2d-4b75-4217-8ff2-3ec5625d1a35 | 35 |
| java.util.UUID:1f0a203d-9bd5-49c7-a333-a74e423c7f10 | 15 |
| java.util.UUID:aaf0fc4a-a2e0-48b4-93cb-7529d5a62239 | 3 |
| jitc-2021-002447.pdf | 2 |
Top country views
| views | |
|---|---|
| United States | 2 |
Top city views
| views | |
|---|---|
| Indianapolis | 2 |